Literature DB >> 16178478

Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?

Terhi A Martikainen1, Anna-Maija Teppo, Carola Grönhagen-Riska, Agneta V Ekstrand.   

Abstract

OBJECTIVES: Glucose and other bioincompatible factors of conventional peritoneal dialysis solutions may damage the peritoneal membrane. The aim of our study was to investigate whether replacement of glucose with icodextrin (ID) or amino acids (AA) affects inflammatory parameters or cancer antigen 125 (CA125).
DESIGN: Either ID or AA was used, in random order, in one daily exchange during an 8-week period. After the first study period, the patients entered a washout period and then switched to the other study solution for an 8-week period. C-reactive protein (CRP) was measured in serum, and CA125, tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), soluble intercellular adhesion molecule-1 (sICAM-1), and hyaluronan (HA) were measured in the overnight dwell dialysates at the beginning and end of the study periods.
SETTING: A university hospital. PATIENTS: 22 patients with duration on peritoneal dialysis of 1.5 - 6.3 months. MAIN OUTCOME MEASURES: Levels of serum CRP and dialysate CA125, IL-6, HA, and sICAM-1 during use of ID and AA were compared to levels during use of glucose-only-based solutions.
RESULTS: CRP increased significantly during use of ID. CA125 increased significantly during 8 weeks' use of AA, from 22.8 (5.4 - 89.0) to 42.9 (7.1 - 92.9) kU/L (p = 0.007). IL-6 increased during 8 weeks' use of AA, from 22.0 (9.0 - 108.0) to 36.5 (14.0 - 93.0) ng/L (p = 0.002) and ID, from 25.5 (8.0 - 82.0) to 40.0 (12.0 - 118.0) ng/L (p = 0.008). TNF-alpha also increased significantly during use of ID, but showed no significant changes during use of AA.
CONCLUSIONS: The use of glucose-free solutions, especially AA, may lead to preservation of mesothelial cell mass and host defense. However, activation of systemic and peritoneal inflammation may appear during the use of ID and to a lesser extent during use of AA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16178478

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  20 in total

1.  Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.

Authors:  Sylvie Opatrna; Daniel Lysak; Ladislav Trefil; Clare Parker; Nicholas Topley
Journal:  Perit Dial Int       Date:  2012 Jan-Feb       Impact factor: 1.756

2.  Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial.

Authors:  Yuji Takatori; Shigeru Akagi; Hitoshi Sugiyama; Junko Inoue; Shoichiro Kojo; Hiroshi Morinaga; Kazushi Nakao; Jun Wada; Hirofumi Makino
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 8.237

3.  Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.

Authors:  Susan Yung; Sing Leung Lui; Chris K F Ng; Andrew Yim; Maggie K M Ma; Kin Yee Lo; Chik Cheung Chow; Kwok Hong Chu; Wai Leung Chak; Man Fai Lam; Chun Yu Yung; Terence P S Yip; Sunny Wong; Colin S O Tang; Flora S K Ng; Tak Mao Chan
Journal:  Perit Dial Int       Date:  2015 Mar-Apr       Impact factor: 1.756

Review 4.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

Review 5.  An update on peritoneal dialysis solutions.

Authors:  Elvia García-López; Bengt Lindholm; Simon Davies
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

6.  A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.

Authors:  Kar Neng Lai; Man Fai Lam; Joseph C K Leung; Loretta Y Chan; Christopher W K Lam; Iris H S Chan; Hoi Wong Chan; Chun Sang Li; Sunny S H Wong; Yiu Wing Ho; Au Cheuk; Matthew K L Tong; Sydney C W Tang
Journal:  Perit Dial Int       Date:  2011-11-03       Impact factor: 1.756

7.  A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation.

Authors:  Caatje Y le Poole; Angelique G A Welten; Piet M ter Wee; Nanne J Paauw; Amina N Djorai; Rob M Valentijn; Robert H J Beelen; Jacob van den Born; Frans J van Ittersum
Journal:  Perit Dial Int       Date:  2011-11-01       Impact factor: 1.756

8.  Phenotypes of encapsulating peritoneal sclerosis--macroscopic appearance, histologic findings, and outcome.

Authors:  Joerg Latus; Christoph Ulmer; Peter Fritz; Bianka Rettenmaier; Dagmar Biegger; Thomas Lang; German Ott; Martin Kimmel; Wolfgang Steurer; M Dominik Alscher; Stephan Segerer; Niko Braun
Journal:  Perit Dial Int       Date:  2013-02-01       Impact factor: 1.756

9.  Biocompatibility of a bicarbonate-buffered amino-acid-based solution for peritoneal dialysis.

Authors:  Thorsten O Bender; Janusz Witowski; Christoph Aufricht; Michaela Endemann; Ulrich Frei; Jutta Passlick-Deetjen; Achim Jörres
Journal:  Pediatr Nephrol       Date:  2008-05-15       Impact factor: 3.714

Review 10.  Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death?

Authors:  Harpaul Cheema; Joanne M Bargman
Journal:  Perit Dial Int       Date:  2013 Jul-Aug       Impact factor: 1.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.